Click on headlines below to download research

Onwards and upwards
Oasmia Pharmaceutical | 12/03/2021

Oasmia is at a major inflection point as it focuses on its transformation into an R&D-driven, specialty pharma company, with commercially available assets.…

Clarity on pathway to US approval
Oasmia Pharmaceutical | 17/12/2020

Oasmia’s H1 FY21 results highlight recent developments made to realign the business. In December, global partner Elevar Therapeutics announced it…

Executive interview
Oasmia Pharmaceutical – executive interview | 17/12/2020

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through…

An appealing metamorphosis
Oasmia Pharmaceutical | 09/09/2020

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform…